NCT06342609View on ClinicalTrials.gov

Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

September 7, 2024

Study Completion Date

September 7, 2024

Conditions
Coronary Artery Disease
Interventions
DRUG

Colchicine 0.5 MG

0.5mg per day of Colchicine orally administered

Trial Locations (1)

90502

Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance

All Listed Sponsors
lead

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER